A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)-Reference-Cited by-同舟云学术

A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)

Published:2006-05 Issue:7 Volume:42 Page:882-887
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Coleman R.E.,Biganzoli L.,Canney P.,Dirix L.,Mauriac L.,Chollet P.,Batter V.,Ngalula-Kabanga E.,Dittrich C.,Piccart M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference9 articles.

1. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes;Gabizon;Cancer Res.,1994

2. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas – rationale for combination with radiotherapy;Koukourakis;Acta Oncol.,2000

3. Treatment of advanced breast cancer with sterically stabilised liposomal doxorubicin: results of a multicentre phase II trial;Ransom;J. Clin. Oncol.,1997

4. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer;O’Brien;Ann. Oncol.,2004

5. Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer;Campos;The Oncologist,2003

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16);European Journal of Cancer;2024-04

2. Docetaxel-loaded nanoformulations delivery for breast cancer management: Challenges, recent advances, and future perspectives;Journal of Drug Delivery Science and Technology;2024-02

3. Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives;Journal of Pharmaceutical Sciences;2023-11

4. Pegylated liposomal doxorubicin (PLD) in daily practice—A single center experience of treatment with PLD in patients with comorbidities and older patients with metastatic breast cancer;Cancer Medicine;2023-05-06

5. Evaluation of the in vitro and in vivo effect of liposomal doxorubicin along with oncolytic Newcastle disease virus on 4T1 cell line: Animal preclinical research;Veterinary Medicine and Science;2023-03-15